Overview

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

Status:
Completed
Trial end date:
2016-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to gather information on the effectiveness and tolerability of a novel composition of existing U.S. Food and Drug Administration (FDA) approved topical medications for the treatment of moderate to severe melasma.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic